IMMUNOCORE HLDGS ADS/1 (6YG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, IMMUNOCORE HLDGS ADS/1 (6YG) has a cash flow conversion efficiency ratio of -0.086x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-32.66 Million ≈ $-38.18 Million USD) by net assets (€381.03 Million ≈ $445.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of IMMUNOCORE HLDGS ADS/1 to measure how much of total assets are equity-financed.
IMMUNOCORE HLDGS ADS/1 - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how IMMUNOCORE HLDGS ADS/1's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is IMMUNOCORE HLDGS ADS/1's earnings quality to evaluate the quality of earnings relative to operating cash generation.
IMMUNOCORE HLDGS ADS/1 Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IMMUNOCORE HLDGS ADS/1 ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jilin OLED Material Tech Co Ltd
SHG:688378
|
-0.012x |
|
Nusantara Sawit Sejahtera
JK:NSSS
|
0.079x |
|
Alphamin Res
V:AFM
|
0.124x |
|
Kepco Plant S&
KO:051600
|
0.008x |
|
Zhejiang Jiahua Energy Chemical Industry Co Ltd
SHG:600273
|
0.025x |
|
NAPCO Security Technologies Inc
NASDAQ:NSSC
|
0.072x |
|
IMDEX Ltd
AU:IMD
|
0.085x |
|
CTS Corporation
NYSE:CTS
|
0.053x |
Annual Cash Flow Conversion Efficiency for IMMUNOCORE HLDGS ADS/1 (2022–2025)
The table below shows the annual cash flow conversion efficiency of IMMUNOCORE HLDGS ADS/1 from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see 6YG market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €381.03 Million ≈ $445.47 Million |
€-10.71 Million ≈ $-12.52 Million |
-0.028x | -138.91% |
| 2024-12-31 | €360.72 Million ≈ $421.71 Million |
€26.06 Million ≈ $30.47 Million |
0.072x | +806.40% |
| 2023-12-31 | €368.84 Million ≈ $431.22 Million |
€2.94 Million ≈ $3.44 Million |
0.008x | +105.49% |
| 2022-12-31 | €338.90 Million ≈ $396.21 Million |
€-49.21 Million ≈ $-57.53 Million |
-0.145x | -- |
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more